April 27, 2018 / 4:17 PM / 3 months ago

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

April 27 (Reuters) - UCB SA:

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

* EUROPEAN COMMISSION’S ENDORSEMENT OF CHMP POSITIVE OPINION FOR PSORIASIS EXPECTED IN Q2

* CHMP POSITIVE OPINION IS BASED ON DATA FROM A PHASE 3 CLINICAL DEVELOPMENT PROGRAM CONSISTING OF CIMPASI-1, CIMPASI-2 AND CIMPACT

* THIS WOULD FURTHER BROADEN CLINICAL VALUE OF CIMZIA Source text : bit.ly/2JweDGq Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below